Jay Moyes
About Jay M. Moyes
Jay M. Moyes (age 71) is Puma Biotechnology’s Lead Independent Director and has served on the Board since April 2012. He chairs the Audit Committee and is a member of the Compensation Committee; the Board has designated him an audit committee financial expert and affirmed his independence under NASDAQ and SEC rules. His background includes CFO roles at Myriad Genetics (1996–2007), XDx/CareDx (2008–2009), and Amedica (2013–2014), senior positions at KPMG (1979–1991), and service on multiple life sciences boards. Moyes holds an MBA from the University of Utah and a BA in Economics from Weber State University and is a former CPA .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Myriad Genetics, Inc. | Chief Financial Officer; VP Finance | 1996–2007 (CFO); 1993–2005 (VP Finance) | Led finance for a public diagnostics company; deep SEC and capital markets experience . |
| XDx (now CareDx), Inc. | Chief Financial Officer | 2008–2009 | Private molecular diagnostics; growth-stage finance leadership . |
| Amedica/SINTX Technologies | Chief Financial Officer | Oct 2013–Aug 2014 | Orthopedic implant company; later returned to board service . |
| KPMG LLP | Senior Manager | 1979–1991 | Audit and accounting expertise; foundation for audit committee oversight . |
| Utah Life Science Association | Board of Trustees | 1999–2006 | Industry network and advocacy engagement . |
External Roles
| Company | Role | Tenure start | Notes |
|---|---|---|---|
| SINTX Technologies (public) | Director | Apr 2025 | Previously CFO (2013–2014) and director (2012–2014) . |
| BioCardia, Inc. (public) | Director | Jan 2011 | Cardiovascular regenerative medicine . |
| Achieve Life Sciences, Inc. (public) | Director (former) | Aug 2017–May 2023 | Specialty pharma . |
| Predictive Technology Group, Inc. (public) | Director (former) | Feb 2019–Dec 2019 | Molecular diagnostics and regenerative medicine . |
| Osiris Therapeutics, Inc. (public) | Director (former) | May 2006–Dec 2017 | Bio-surgery company . |
Board Governance
- Lead Independent Director; presides over executive sessions and liaises between independent directors and the CEO/Chair .
- Committee assignments: Audit (Chair), Compensation (Member). The Board determined Moyes is independent and an “audit committee financial expert.” Audit Committee met five times in FY2024; Compensation Committee met five times .
- Independence: The Board concluded 7 of 8 directors are independent, including Moyes .
- Attendance: All directors attended at least 75% of Board and committee meetings in FY2024; non-employee directors held four Board executive sessions (Moyes presided) .
- Related-party oversight: As Audit Chair, Moyes oversees approval of related party transactions per Item 404 and company policy . The proxy outlines the company’s Related Party Transactions Policy; no specific related-party transactions involving Moyes are disclosed in the filing .
Fixed Compensation
| Component (2024) | Amount (USD) | Detail |
|---|---|---|
| Board Annual Retainer | $50,000 | Director Compensation Program schedule . |
| Audit Committee Chair Retainer | $20,000 | Committee chair fee . |
| Compensation Committee Member Retainer | $7,500 | Committee member fee . |
| Total Cash Fees Earned | $77,500 | Reported for Moyes in Director Compensation Table . |
Program notes:
- No per-meeting fees; cash paid quarterly and prorated as needed .
- Independent consultant Compensia reviewed the program; no changes for 2024/2025 .
Performance Compensation
Directors do not receive performance-conditioned equity; annual grants are time-based RSUs.
| Equity Element | Grant mechanics | 2024 grant detail |
|---|---|---|
| Annual RSU Award | Target $300,000 value using 30-day average price; capped at 27,000 shares; vests in full by 1-year anniversary or next annual meeting | 27,000 RSUs granted June 18, 2024 to each non-employee director; reported grant date fair value for Moyes: $83,430 . |
Other Directorships & Interlocks
| Potential Interlock Area | Observation |
|---|---|
| Auditor relationship | PBYI’s auditor is KPMG; Moyes worked at KPMG decades ago (1979–1991). No current employment or disclosed financial ties; independence affirmed by the Board . |
| External boards overlap with PBYI | No disclosed transactions with SINTX or BioCardia; Audit Chair reviews related-party transactions; none involving Moyes are disclosed in proxy . |
| Overboarding risk | Company guidelines cap public boards at five (three if a sitting public-company CEO). Moyes’ current public boards (PBYI, SINTX, BioCardia) comply . |
Expertise & Qualifications
- Finance and accounting leadership; audit oversight and SEC reporting experience (CFO roles at multiple public companies; former KPMG) .
- Life sciences operating and board experience across diagnostics, therapeutics, and medical devices .
- Designated audit committee financial expert; former CPA .
Equity Ownership
| Category | Shares/Units | Notes |
|---|---|---|
| Direct/common shares held | 21,322 | As of April 21, 2025 . |
| Unvested RSUs vesting within 60 days | 27,000 | Counted toward ownership guidelines . |
| Options exercisable within 60 days | 47,604 | Director options outstanding . |
| Total beneficial ownership | 95,926 | “Less than 1%” of shares outstanding . |
Ownership alignment safeguards:
- Director ownership guidelines: minimum 10,000 shares (legacy); revised to 3x annual cash retainer by Dec 31, 2029, with RSUs counting and options excluded; directors with ≥3 years of service met the prior requirement as of 12/31/2024 .
- Hedging and pledging of company stock prohibited for directors .
Governance Assessment
- Strengths: Independent Lead Director with deep finance/audit credentials; Audit Chair and designated financial expert; active oversight of financial reporting, cybersecurity risk, and related-party transactions; consistent attendance and engagement; equity-based director pay with ownership guidelines supporting alignment .
- Compensation structure: Cash retainer plus time-based RSUs; program reviewed by independent consultant, unchanged in 2024/2025, avoiding overly complex or discretionary director pay .
- Risk indicators: Historical KPMG employment noted but remote and non-current; no disclosed related-party transactions or pledging/hedging; overboarding mitigated by internal limits and current board count .
- Context signal: 2024 say-on-pay approval for NEOs was ~96%, indicating constructive shareholder sentiment toward compensation governance broadly, though not director-specific .